Lack of significant food effect on the pharmacokinetics of ticagrelor in healthy volunteers

Journal of Clinical Pharmacy and Therapeutics

Volumn 37, Issue 4, 2012, Pages 464-468

  Teng, R ^a   Mitchell, P D ^a   Butler, K ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

antiplatelet therapy; food effect; P2Y 12 receptor antagonist; pharmacokinetics; ticagrelor

Indexed keywords

AR C 124910 XX; DRUG METABOLITE; TICAGRELOR; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CALORIC INTAKE; CROSSOVER PROCEDURE; DIET RESTRICTION; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; EPISTAXIS; FEMALE; FOOD DRUG INTERACTION; FOOD INTAKE; HEADACHE; HUMAN; HUMAN EXPERIMENT; LIPID DIET; MALE; MAXIMUM PLASMA CONCENTRATION; MEAL; NORMAL HUMAN; NOSE CONGESTION; OPEN STUDY; RANDOMIZATION; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADENOSINE; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AREA UNDER CURVE; CROSS-OVER STUDIES; DIETARY FATS; FEMALE; FOOD-DRUG INTERACTIONS; HUMANS; LEAST-SQUARES ANALYSIS; MALE; MIDDLE AGED; PURINERGIC P2Y RECEPTOR ANTAGONISTS; TIME FACTORS; YOUNG ADULT;

EID: 84863424844     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2011.01307.x     Document Type: Article

References (20)

1. Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. European Heart Journal, 2007; 28: 1598-1660.
2. Husted S, van Giezen JJ,. Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist. Cardiovascular Therapeutics, 2009; 27: 259-274.
3. Cannon CP, Husted S, Harrington RA, et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. Journal of the American College of Cardiology, 2007; 50: 1844-1851. (Pubitemid 350007959)
4. 12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. Journal of the American College of Cardiology, 2007; 50: 1852-1856. (Pubitemid 350017792)
5. James S, Akerblom A, Cannon CP, et al. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. American Heart Journal, 2009; 157: 599-605.
6. Brilique, summary of product characteristics. 2010. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/001241/WC500100494.pdf (accessed 16 September 2011).
7. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. New England Journal of Medicine, 2009; 361: 1045-1057.
8. Fleisher D, Li C, Zhou Y, Pao LH, Karim A,. Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications. Clinical Pharmacokinetics, 1999; 36: 233-254. (Pubitemid 29178760)
9. Schmidt LE, Dalhoff K,. Food-drug interactions. Drugs, 2002; 62: 1481-1502. (Pubitemid 34804156)
10. Harris RZ, Jang GR, Tsunoda S,. Dietary effects on drug metabolism and transport. Clinical Pharmacokinetics, 2003; 42: 1071-1088. (Pubitemid 37357646)
11. Lentz KA,. Current methods for predicting human food effect. The AAPS Journal, 2008; 10: 282-288.
12. Camilleri M,. Integrated upper gastrointestinal response to food intake. Gastroenterology, 2006; 131: 640-658. (Pubitemid 44142441)
13. Singh BM, Malhotra BK,. Effects of food on the clinical pharmacokinetics of anticancer agents: underlying mechanisms and implications for oral chemotherapy. Clinical Pharmacokinetics, 2004; 43: 1127-1156. (Pubitemid 40013180)
14. Gershkovich P, Hoffman A,. Effect of a high-fat meal on absorption and disposition of lipophilic compounds: the importance of degree of association with triglyceride-rich lipoproteins. European Journal of Pharmaceutical Sciences, 2007; 32: 24-32. (Pubitemid 47102188)
15. 12 receptor antagonist, in healthy subjects. European Journal of Clinical Pharmacology, 2010; 66: 487-496.
16. Butler K, Teng R,. Pharmacokinetics, pharmacodynamics and safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers. British Journal of Clinical Pharmacology, 2010; 70: 65-77.
17. FDA (2002) Guidance for industry: food-effect bioavailability and fed bioequivalence studies, December 2002. Available at: http://www.fda.gov/ downloads/RegulatoryInformation/Guidances/UCM126833.pdf (accessed 16 September 2011).
18. Sillén H, Cook M, Davis P,. Determination of ticagrelor and two metabolites in plasma samples by liquid chromatography and mass spectrometry. Journal of Chromatography B, 2010; 878: 2299-2306.
19. Fatouros DG, Karpf DM, Nielsen FS, Mullertz A,. Clinical studies with oral lipid based formulations of poorly soluble compounds. Therapeutics and Clinical Risk Management, 2007; 3: 591-604. (Pubitemid 47496964)
20. Butler K, Teng R,. Pharmacokinetics, pharmacodynamics and safety of ticagrelor in volunteers with mild hepatic impairment. Journal of Clinical Pharmacology, 2011; 51: 978-987.